AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-56. (Canceled)

57. (Previously presented) A method for identifying a compound which inhibits the binding of a SLIC-1 protein to PSGL-1, comprising:

i) contacting said SLIC-1 protein with a test compound; and

ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

1) a SLIC-1 moiety chosen from:

(a) amino acids 1-226 of SEQ ID NO:2;

(b) amino acids 1-316 of SEQ ID NO:2; and

(c) fragments of (a) or (b) that have PSGL-1 binding activity; and

2) optionally, at least one heterologous amino acid sequence.

58. (Previously presented) A method for identifying a compound which increases the binding of a SLIC-1 protein to PSGL-1, comprising:

i) contacting said SLIC-1 protein with a test compound; and

ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

1) a SLIC-1 moiety chosen from:

(a) amino acids 1-226 of SEQ ID NO:2;

(b) amino acids 1-316 of SEQ ID NO:2; and

(c) fragments of (a) or (b) that have PSGL-1 binding activity; and

2) optionally, at least one heterologous amino acid sequence.

59. (Previously presented) The method of claim 57, wherein at least one heterologous sequence is a protein tag.

60. (Previously presented) The method of claim 59, wherein said protein tag is a GST tag.

61. (Previously presented) The method of claim 59, wherein said protein tag is a T7 tag.

62. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2.

63. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2 and a protein tag.

64. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2.

65. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2 and a protein tag.

66. (Currently amended) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids ~~1-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

67. (Currently amended) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids ~~1-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

68. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

69. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

70. (Previously presented) The method of claim 58, wherein at least one heterologous sequence is a protein tag.

71. (Previously presented) The method of claim 70, wherein said protein tag is a GST tag.

72. (Previously presented) The method of claim 70, wherein said protein tag is a T7 tag.

73. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2.

74. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2 and a protein tag.

75. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2.

76. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2 and a protein tag.

77. (Currently amended) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids ~~1-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

78. (Currently amended) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids ~~1-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

79. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

80. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

81. (Previously presented) A method for identifying a compound which inhibits the binding of a SLIC-1 protein to PSGL-1, comprising:

i) contacting said SLIC-1 protein with a test compound; and

ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

1) a SLIC-1 moiety having PSGL-1 binding activity chosen from:

(a) an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2;

(b) an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2; and

(c) fragments of (a) or (b); and

2) optionally, at least one heterologous amino acid sequence.

82. (Previously presented) A method for identifying a compound which increases the binding of a SLIC-1 protein to PSGL-1, comprising:

I) contacting said SLIC-1 protein with a test compound; and

ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

1) a SLIC-1 moiety having PSGL-1 binding activity chosen from:

(a) an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2;

(b) an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2; and

(c) fragments of (a) or (b); and

2) optionally, at least one heterologous amino acid sequence.

83. (Previously presented) The method of claim 81, wherein at least one heterologous sequence is a protein tag.

84. (Previously presented) The method of claim 83, wherein said protein tag is a GST tag.

85. (Previously presented) The method of claim 83, wherein said protein tag is a T7 tag.

86. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2.

87. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2 and a protein tag.

88. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2.

89. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2 and a protein tag.

90. (Currently amended) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids ~~1-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

91. (Currently amended) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids ~~1-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

92. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

93. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

94. (Previously presented) The method of claim 82, wherein at least one heterologous sequence is a protein tag.

95. (Previously presented) The method of claim 94, wherein said protein tag is a GST tag.

96. (Previously presented) The method of claim 94, wherein said protein tag is a T7 tag.

97. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2.

98. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2 and a protein tag.

99. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2.

100. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2 and a protein tag.

101. (Currently amended) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids ~~1-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

102. (Currently amended) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids ~~1-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.

103. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

104. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.